Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial
Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure...
Gespeichert in:
Veröffentlicht in: | Hormone research in paediatrics 2015-01, Vol.83 (5), p.321-331 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 331 |
---|---|
container_issue | 5 |
container_start_page | 321 |
container_title | Hormone research in paediatrics |
container_volume | 83 |
creator | Bakker, N.E. Siemensma, E.P.C. Koopman, C. Hokken-Koelega, A.C.S. |
description | Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p < 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment. |
doi_str_mv | 10.1159/000374113 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_25764996</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1686420070</sourcerecordid><originalsourceid>FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</originalsourceid><addsrcrecordid>eNpd0cFu1DAQBmALgWhVeuCOkCUuIBGwncSJeyvL0laqBCqLOEZOPNm6dewwcVSW1-PF8Gq3e0A-eCR_Mxr5J-QlZx84L9VHxlheFZznT8gxlzLPRC3k00PN6yNyOk13bOvqSvHqOTkSZSULpeQx-fvZQtS4oUsPuN7QKx_1Pbynn4LZ0EUYxjDZaIOn2ht6A1O0fv1ol79H8MbGGYFaT78hjHMLGLWji1vrDIKnDzbephdtALOf1jlLv2-8wTAAbaEPqXM72My4nXuB4SHxy4BD8EBXCDoO4OMZPac3yYXB_gGT1vIRg3OpXKHV7gV51ms3wen-PiE_vixXi8vs-uvF1eL8OuvyvIgZcCMF54r1sixAC1b06XSqhl4WXdtr0KbgnepAdEbksq5bURrT1q3SSsguPyFvd3NHDL_m9BfNYKcOnNMewjw1XNayEIxVLNE3_9G7MKNP2yWlSlWxuhRJvdupDsM0IfTNiHZIaTScNdtwm0O4yb7eT5zbAcxBPkaZwKsduNe4BjyAff8_1IWrFg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1695970852</pqid></control><display><type>article</type><title>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</title><source>MEDLINE</source><source>Karger Journals</source><source>Alma/SFX Local Collection</source><creator>Bakker, N.E. ; Siemensma, E.P.C. ; Koopman, C. ; Hokken-Koelega, A.C.S.</creator><creatorcontrib>Bakker, N.E. ; Siemensma, E.P.C. ; Koopman, C. ; Hokken-Koelega, A.C.S.</creatorcontrib><description>Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p < 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.</description><identifier>ISSN: 1663-2818</identifier><identifier>EISSN: 1663-2826</identifier><identifier>DOI: 10.1159/000374113</identifier><identifier>PMID: 25764996</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Body Composition - drug effects ; Body Composition - physiology ; Child ; Child, Preschool ; Diet ; Energy Intake - drug effects ; Energy Intake - physiology ; Energy Metabolism - drug effects ; Energy Metabolism - physiology ; Female ; Human Growth Hormone - pharmacology ; Human Growth Hormone - therapeutic use ; Humans ; Infant ; Male ; Motor Activity - drug effects ; Motor Activity - physiology ; Original Paper ; Prader-Willi Syndrome - drug therapy ; Prader-Willi Syndrome - physiopathology ; Treatment Outcome</subject><ispartof>Hormone research in paediatrics, 2015-01, Vol.83 (5), p.321-331</ispartof><rights>2015 S. Karger AG, Basel</rights><rights>2015 S. Karger AG, Basel.</rights><rights>Copyright (c) 2015 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</citedby><cites>FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2422,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25764996$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bakker, N.E.</creatorcontrib><creatorcontrib>Siemensma, E.P.C.</creatorcontrib><creatorcontrib>Koopman, C.</creatorcontrib><creatorcontrib>Hokken-Koelega, A.C.S.</creatorcontrib><title>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</title><title>Hormone research in paediatrics</title><addtitle>Horm Res Paediatr</addtitle><description>Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p < 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.</description><subject>Body Composition - drug effects</subject><subject>Body Composition - physiology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Diet</subject><subject>Energy Intake - drug effects</subject><subject>Energy Intake - physiology</subject><subject>Energy Metabolism - drug effects</subject><subject>Energy Metabolism - physiology</subject><subject>Female</subject><subject>Human Growth Hormone - pharmacology</subject><subject>Human Growth Hormone - therapeutic use</subject><subject>Humans</subject><subject>Infant</subject><subject>Male</subject><subject>Motor Activity - drug effects</subject><subject>Motor Activity - physiology</subject><subject>Original Paper</subject><subject>Prader-Willi Syndrome - drug therapy</subject><subject>Prader-Willi Syndrome - physiopathology</subject><subject>Treatment Outcome</subject><issn>1663-2818</issn><issn>1663-2826</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpd0cFu1DAQBmALgWhVeuCOkCUuIBGwncSJeyvL0laqBCqLOEZOPNm6dewwcVSW1-PF8Gq3e0A-eCR_Mxr5J-QlZx84L9VHxlheFZznT8gxlzLPRC3k00PN6yNyOk13bOvqSvHqOTkSZSULpeQx-fvZQtS4oUsPuN7QKx_1Pbynn4LZ0EUYxjDZaIOn2ht6A1O0fv1ol79H8MbGGYFaT78hjHMLGLWji1vrDIKnDzbephdtALOf1jlLv2-8wTAAbaEPqXM72My4nXuB4SHxy4BD8EBXCDoO4OMZPac3yYXB_gGT1vIRg3OpXKHV7gV51ms3wen-PiE_vixXi8vs-uvF1eL8OuvyvIgZcCMF54r1sixAC1b06XSqhl4WXdtr0KbgnepAdEbksq5bURrT1q3SSsguPyFvd3NHDL_m9BfNYKcOnNMewjw1XNayEIxVLNE3_9G7MKNP2yWlSlWxuhRJvdupDsM0IfTNiHZIaTScNdtwm0O4yb7eT5zbAcxBPkaZwKsduNe4BjyAff8_1IWrFg</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Bakker, N.E.</creator><creator>Siemensma, E.P.C.</creator><creator>Koopman, C.</creator><creator>Hokken-Koelega, A.C.S.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</title><author>Bakker, N.E. ; Siemensma, E.P.C. ; Koopman, C. ; Hokken-Koelega, A.C.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c334t-e1d621190f654ea204f4f4c98ef64cbfaead41c9ce2cd23688b25ddb8b9a926c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Body Composition - drug effects</topic><topic>Body Composition - physiology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Diet</topic><topic>Energy Intake - drug effects</topic><topic>Energy Intake - physiology</topic><topic>Energy Metabolism - drug effects</topic><topic>Energy Metabolism - physiology</topic><topic>Female</topic><topic>Human Growth Hormone - pharmacology</topic><topic>Human Growth Hormone - therapeutic use</topic><topic>Humans</topic><topic>Infant</topic><topic>Male</topic><topic>Motor Activity - drug effects</topic><topic>Motor Activity - physiology</topic><topic>Original Paper</topic><topic>Prader-Willi Syndrome - drug therapy</topic><topic>Prader-Willi Syndrome - physiopathology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bakker, N.E.</creatorcontrib><creatorcontrib>Siemensma, E.P.C.</creatorcontrib><creatorcontrib>Koopman, C.</creatorcontrib><creatorcontrib>Hokken-Koelega, A.C.S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hormone research in paediatrics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bakker, N.E.</au><au>Siemensma, E.P.C.</au><au>Koopman, C.</au><au>Hokken-Koelega, A.C.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial</atitle><jtitle>Hormone research in paediatrics</jtitle><addtitle>Horm Res Paediatr</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>83</volume><issue>5</issue><spage>321</spage><epage>331</epage><pages>321-331</pages><issn>1663-2818</issn><eissn>1663-2826</eissn><abstract>Background/Aims: Dietary management is a difficult but key aspect of care in children with Prader-Willi syndrome (PWS). We therefore investigated the effect of growth hormone (GH) treatment on reported energy intake in children with PWS, in relation with body composition, resting energy expenditure (REE) and hormone levels. Methods: In a randomized controlled GH trial including 47 children with PWS, we assessed 5-day dietary records and dual-energy X-ray absorptiometry for body composition. REE was calculated by Müller's equation, based on fat mass, fat free mass and gender. Results: Baseline energy intake of children with PWS was lower than normal daily energy requirements (p < 0.001), and decreased with age to 50% in prepubertal children. Energy intake in infants [m/f: 11/8; median (interquartile range [IQR]) age 2.7 years (1.5-3.2)] increased after 1 year of GH treatment (p = 0.008); this tended to be higher in the GH group than in the untreated group (p = 0.07). In prepubertal children [m/f: 14/14; median (IQR) age 6.8 years (5.1-8.1)], the increase in energy intake was higher in the GH group, but this was not different compared to the untreated group. REE was not different between the GH group and the untreated group. Increase in energy intake during 2 years of GH treatment was correlated with lower fat percentage standard deviation scores (p = 0.037) and higher adiponectin levels (p = 0.007). Conclusion: Our study demonstrates that parents of children with PWS are very well capable of restricting energy intake up to 50% compared to daily energy requirements for age- and sex-matched healthy children. GH treatment was associated with a slight increase in energy intake, but also improved body composition and adiponectin levels, which suggests a protective effect of GH treatment.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>25764996</pmid><doi>10.1159/000374113</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1663-2818 |
ispartof | Hormone research in paediatrics, 2015-01, Vol.83 (5), p.321-331 |
issn | 1663-2818 1663-2826 |
language | eng |
recordid | cdi_pubmed_primary_25764996 |
source | MEDLINE; Karger Journals; Alma/SFX Local Collection |
subjects | Body Composition - drug effects Body Composition - physiology Child Child, Preschool Diet Energy Intake - drug effects Energy Intake - physiology Energy Metabolism - drug effects Energy Metabolism - physiology Female Human Growth Hormone - pharmacology Human Growth Hormone - therapeutic use Humans Infant Male Motor Activity - drug effects Motor Activity - physiology Original Paper Prader-Willi Syndrome - drug therapy Prader-Willi Syndrome - physiopathology Treatment Outcome |
title | Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-23T14%3A53%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dietary%20Energy%20Intake,%20Body%20Composition%20and%20Resting%20Energy%20Expenditure%20in%20Prepubertal%20Children%20with%20Prader-Willi%20Syndrome%20before%20and%20during%20Growth%20Hormone%20Treatment:%20A%20Randomized%20Controlled%20Trial&rft.jtitle=Hormone%20research%20in%20paediatrics&rft.au=Bakker,%20N.E.&rft.date=2015-01-01&rft.volume=83&rft.issue=5&rft.spage=321&rft.epage=331&rft.pages=321-331&rft.issn=1663-2818&rft.eissn=1663-2826&rft_id=info:doi/10.1159/000374113&rft_dat=%3Cproquest_pubme%3E1686420070%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1695970852&rft_id=info:pmid/25764996&rfr_iscdi=true |